Review on NOL4L, with data on DNA, on the protein encoded, and where the gene is implicated.
Description
Two coding proteins: NOL4L-010, from: 11 exons; transcript length: 6,577 bps translation: 680 amino acids; and NOL4L-001, from: 8 exons; transcript length: 5,991 bps translation: 436 amino acids. A Poly-Asp is found at aa 161 to 169 according to Vega (http://vega.archive.ensembl.org/Homo_sapiens/Ge ne/Summary?db=core;g=OTTHUMG00000032219 ;r=20: and UniProt (https://www.uniprot.org/uniprot/Q96MY1#express ion).
Expression
Expressed in all tissues; High expression in the testis, and, to a lesser extend, in the small intestine,other digestive organs, brain and bone marrow. NOL4L orthologs are present in most vertebrates and are well conserved.
In zebrafish embryos, Znol4lb (the zebrafish nol4l with the highest identity with human NOL4L) mRNA is localized to the intermediate mesoderm. It is expressed in the central nervous system, pronephros, the gut and, at low levels, in the hematopoietic cells (Borah et al. 2016 ).
Localisation
Mainly localized to the nucleoplasm.
Function
Acccording to BioGRID (https://thebiogrid.org/12665), interacts with: CTBP1 (C-terminal binding protein 1), corepressor targeting various transcription regulators. TEX9 (testis expressed 9). SRPK1 (SRSF protein kinase 1), involved in the regulation of splicing via phosphorylation of splicing factors. CTBP2 (C-terminal binding protein 2), corepressor targeting various transcription regulators. SKA3 (spindle and kinetochore associated complex subunit 3), component of a microtubule-binding complex essential for chromosome segregation. TRIM25 (tripartite motif containing 25), ubiquitin E3 ligase. MIR206 (microRNA 206). (Asmann et al. 2012 ).
Implicated in
fusion/translocation t(17;20)(q22;q11) MMD/NOL4L in breast adenocarcinoma (Yoshihara et al. 2015) .
-fusion 20q11-20q11 NOL4L/ COMMD7 in breast adenocarcinoma (Yoshihara et al. 2015) .
-fusion 20q11-20q11 NOL4L/ EFCAB8 in malignant melanoma of the skin (Hu et al., 2018) .
-fusion 20q11-20q11 PDRG1/NOL4L in malignant epithelial tumor of the uterus corpus (Hu et al., 2018) .
Pediatric acute lymphoblastic leukemia (ALL)
Note 5 cases of dic(9;20) (p13;q11) PAX5/NOL4L available to date (Nebral et al., 2007; Kawamata et al., 2008; Kawamata et al. 2012) .
Hybrid/Mutated gene
In one case, exon 5 of PAX5 was fused to exon 8 of NOL4L, and in four cases, exon 8 of PAX5 was fused to exon 3 of NOL4L, producing two proteins, a short (PAX5/C20ORF112S) and long (PAX5/C20ORF112L) form, localizing in the nucleus, and/or in the cytoplasm and the nucleus (Kawamata et al., 2008) . Oncogenesis Four downstream target genes of PAX5 ( ATP1B1, BLK, SEPT2 and TCF7L2) were down-regulated by induction of PAX5/NOL4L. Loss of the C-terminal end of PAX5 may play role in generation of a dominant negative form of mutated PAX5 (Kawamata et al., 2008) .
Acute myeloid leukemia (AML)
Note A 62-year-old man was diagnosed with AML with maturation (M2-AML), and presented with a t(20;21)(q11.2;q22.1) RUNX1/NOL4L accompanied with monosomy 7 (Guastadisegni et al. 2010) . Hybrid/Mutated gene RUNX1 exon 6 was fused to NOL4L exon 8. Oncogenesis Wild-type NOL4L was expressed at low levels in AML and normal bone marrow, whereas the RUNX1/NOL4L was expressed at high levels (Guastadisegni et al. 2010) .
